Melike Ozcelik
Overview
Explore the profile of Melike Ozcelik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahraman S, Hizal M, Demirel B, Guven D, Gumusay O, Uluc B, et al.
BMC Cancer
. 2024 Dec;
24(1):1592.
PMID: 39736618
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2-...
2.
Eser M, Hekimoglu G, Yarar M, Canbek S, Ozcelik M
Sci Rep
. 2024 Nov;
14(1):26581.
PMID: 39496639
Lung cancer remains a significant health challenge, characterized by aberrant tissue growth within the pulmonary system. Early carcinogenic events often involve genomic instability and the emergence of a mutator phenotype....
3.
Yildirim M, Karadurmus N, Okten I, Turk H, Urakci Z, Arslan C, et al.
J Oncol Pharm Pract
. 2024 Apr;
:10781552241241004.
PMID: 38613329
Backgrounds And Objectives: Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of...
4.
Arak H, Erkilic S, Yaslikaya S, Mocan E, Aktas G, Ozdemir M, et al.
J Immunother
. 2024 Feb;
47(5):182-189.
PMID: 38333962
Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV...
5.
Tasci E, Oyan B, Sonmez O, Mutlu A, Atci M, Sakin A, et al.
BMC Cancer
. 2024 Jan;
24(1):114.
PMID: 38262962
No abstract available.
6.
Tasci E, Oyan B, Sonmez O, Mutlu A, Atci M, Sakin A, et al.
BMC Cancer
. 2024 Jan;
24(1):16.
PMID: 38166764
Background: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall...
7.
Akyildiz A, Guven D, Ozluk A, Ismayilov R, Mutlu E, Umit Unal O, et al.
Medicine (Baltimore)
. 2023 Nov;
102(45):e35950.
PMID: 37960746
The aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65...
8.
Unal C, Azizy A, Karabulut S, Tastekin D, Akyildiz A, Yasar S, et al.
Oncologist
. 2023 Sep;
28(10):875-884.
PMID: 37676712
Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). Methods: We conducted...
9.
Aydin D, Kefeli U, Ozcelik M, Erdem G, Sendur M, Yildirim M, et al.
Medicina (Kaunas)
. 2023 Aug;
59(8).
PMID: 37629761
: Small bowel adenocarcinomas (SBAs) are rare tumors of the gastrointestinal system. Lymph node metastasis in patients with curatively resected SBAs is associated with poor prognosis. In this study, we...
10.
Bardakci M, Esmer D, Hafizoglu E, Yaslikaya S, Genc T, Ozcelik M, et al.
Oncology
. 2023 Jun;
101(11):723-729.
PMID: 37379817
Introduction: In the adjuvant treatment of low-risk stage III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since...